{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:45:00Z","timestamp":1785577500348,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81971820"],"award-info":[{"award-number":["No. 81971820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11096-024-01804-z","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T02:09:41Z","timestamp":1730858981000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiac adverse events associated with statins in myocardial infarction patients: a pharmacovigilance analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"47","author":[{"given":"Chuanhuan","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5231-048X","authenticated-orcid":false,"given":"Bimei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"10065","key":"1804_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0140-6736(16)30677-8","volume":"389","author":"GW Reed","year":"2017","unstructured":"Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. Lancet. 2017;389(10065):197\u2013210.","journal-title":"Lancet"},{"issue":"2","key":"1804_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1152\/physrev.00009.2023","volume":"104","author":"S Barrere-Lemaire","year":"2024","unstructured":"Barrere-Lemaire S, Vincent A, Jorgensen C, et al. Mesenchymal stromal cells for improvement of cardiac function following acute myocardial infarction: a matter of timing. Physiol Rev. 2024;104(2):659\u2013725.","journal-title":"Physiol Rev"},{"issue":"1","key":"1804_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12872-023-03231-w","volume":"23","author":"N Salari","year":"2023","unstructured":"Salari N, Morddarvanjoghi F, Abdolmaleki A, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):206.","journal-title":"BMC Cardiovasc Disord"},{"issue":"16","key":"1804_CR4","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","volume":"60","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1804_CR5","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618\u201351.","journal-title":"Circulation"},{"issue":"10","key":"1804_CR6","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1093\/cvr\/cvaa331","volume":"117","author":"TE Kaier","year":"2021","unstructured":"Kaier TE, Alaour B, Marber M. Cardiac troponin and defining myocardial infarction. Cardiovasc Res. 2021;117(10):2203\u201315.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"1804_CR7","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41591-023-02513-2","volume":"29","author":"B Lindahl","year":"2023","unstructured":"Lindahl B, Mills NL. A new clinical classification of acute myocardial infarction. Nat Med. 2023;29(9):2200\u20135.","journal-title":"Nat Med"},{"key":"1804_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.amjcard.2024.03.024","volume":"219","author":"JA Ambrose","year":"2024","unstructured":"Ambrose JA, Kiel R, AlBayati A. Time to tweak the definition of type 2 myocardial infarction. Am J Cardiol. 2024;219:112\u20133.","journal-title":"Am J Cardiol"},{"key":"1804_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2022.06.1019","volume":"354","author":"V Kyto","year":"2022","unstructured":"Kyto V, Saraste A, Tornio A. Early statin use and cardiovascular outcomes after myocardial infarction: a population-based case-control study. Atherosclerosis. 2022;354:8\u201314.","journal-title":"Atherosclerosis"},{"key":"1804_CR10","doi-asserted-by":"crossref","unstructured":"Yoon SS, Dillon CF, Illoh K, et al. Trends in the prevalence of coronary heart disease in the U.S.: National Health and Nutrition Examination Survey, 2001\u20132012. Am J Prev Med. 2016; 51(4): 437\u201345.","DOI":"10.1016\/j.amepre.2016.02.023"},{"issue":"2","key":"1804_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/ehjcvp\/pvac064","volume":"9","author":"V Kyto","year":"2023","unstructured":"Kyto V, Rautava P, Tornio A. Initial statin dose after myocardial infarction and long-term cardiovascular outcomes. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):156\u201364.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"14","key":"1804_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367.","journal-title":"Eur Heart J"},{"key":"1804_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108507","volume":"250","author":"E Raschi","year":"2023","unstructured":"Raschi E, Casula M, Cicero AFG, et al. Beyond statins: new pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacol Ther. 2023;250: 108507.","journal-title":"Pharmacol Ther"},{"key":"1804_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.808712","volume":"9","author":"I Garcia-Fernandez-Bravo","year":"2022","unstructured":"Garcia-Fernandez-Bravo I, Torres-Do-Rego A, Lopez-Farre A, et al. Undertreatment or overtreatment with statins: Where are we? Front Cardiovasc Med. 2022;9: 808712.","journal-title":"Front Cardiovasc Med"},{"key":"1804_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175672","volume":"947","author":"L Alvarez-Jimenez","year":"2023","unstructured":"Alvarez-Jimenez L, Morales-Palomo F, Moreno-Cabanas A, et al. Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis. Eur J Pharmacol. 2023;947: 175672.","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"1804_CR16","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.3390\/ijms21134725","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Jebari S, Larrea-Sebal A, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci. 2020;21(13):4725.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1804_CR17","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","volume":"22","author":"P Vinci","year":"2021","unstructured":"Vinci P, Panizon E, Tosoni LM, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22(21):11687.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1804_CR18","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/ehjci\/jez022","volume":"20","author":"SE Lee","year":"2019","unstructured":"Lee SE, Sung JM, Andreini D, et al. Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study. Eur Heart J Cardiovasc Imaging. 2019;20(11):1307\u201314. https:\/\/doi.org\/10.1093\/ehjci\/jez022.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1804_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.neubiorev.2021.07.012","volume":"128","author":"AJ Walker","year":"2021","unstructured":"Walker AJ, Kim Y, Borissiouk I, et al. Statins: neurobiological underpinnings and mechanisms in mood disorders. Neurosci Biobehav Rev. 2021;128:693\u2013708.","journal-title":"Neurosci Biobehav Rev"},{"key":"1804_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jad.2022.05.113","volume":"311","author":"R De Giorgi","year":"2022","unstructured":"De Giorgi R, Waters S, Pesci NR, et al. The effects of statin monotherapy on depressive symptoms: a systematic review and meta-analysis. J Affect Disord. 2022;311:336\u201343.","journal-title":"J Affect Disord"},{"issue":"12","key":"1804_CR21","volume":"14","author":"SD Gutlapalli","year":"2022","unstructured":"Gutlapalli SD, Farhat H, Irfan H, et al. The anti-depressant effects of statins in patients with major depression post-myocardial infarction: an updated review 2022. Cureus. 2022;14(12): e32323.","journal-title":"Cureus"},{"key":"1804_CR22","doi-asserted-by":"publisher","first-page":"1225794","DOI":"10.3389\/fpsyt.2023.1225794","volume":"14","author":"E Garrels","year":"2023","unstructured":"Garrels E, Kainth T, Silva B, et al. Pathophysiological mechanisms of post-myocardial infarction depression: a narrative review. Front Psychiatry. 2023;14:1225794.","journal-title":"Front Psychiatry"},{"issue":"11","key":"1804_CR23","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. ACC\/AHA guideline on the primary prevention of cardiovascular disease: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-646.","journal-title":"Circulation"},{"key":"1804_CR24","doi-asserted-by":"crossref","unstructured":"Force USPST, Mangione CM, Barry MJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2022; 328(8): 746\u201353.","DOI":"10.1001\/jama.2022.13044"},{"issue":"22","key":"1804_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017915","volume":"9","author":"ST Ahmed","year":"2020","unstructured":"Ahmed ST, Akeroyd JM, Mahtta D, et al. Shared decisions: a qualitative study on clinician and patient perspectives on statin therapy and statin-associated side effects. J Am Heart Assoc. 2020;9(22): e017915.","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"1804_CR26","first-page":"2383","volume":"42","author":"K Gao","year":"2022","unstructured":"Gao K, Cheng F, Li H. Analysis of adverse drug reactions of statins based on FAERS database mining. Chin J Hosp Pharm. 2022;42(22):2383\u20137.","journal-title":"Chin J Hosp Pharm"},{"issue":"1","key":"1804_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jamiaopen\/ooz073","volume":"3","author":"J Chen","year":"2020","unstructured":"Chen J, Wu G, Michelson A, et al. Mining reported adverse events induced by potential opioid-drug interactions. JAMIA Open. 2020;3(1):104\u201312.","journal-title":"JAMIA Open"},{"issue":"8","key":"1804_CR28","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1111\/bcp.15711","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, Krewski D, Mattison DR, et al. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: a disproportionality analysis. Br J Clin Pharmacol. 2023;89(8):2430\u201345.","journal-title":"Br J Clin Pharmacol"},{"key":"1804_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L, et al. Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020;84: 106601.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1804_CR30","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep. 2022;12(1):20601.","journal-title":"Sci Rep"},{"key":"1804_CR31","doi-asserted-by":"crossref","unstructured":"Colantonio LD, Wang Z, Chen L, et al. Trends in high-intensity statin therapy after myocardial infarction among U.S. adults, 2011\u20132019. J Am Coll Cardiol. 2022; 79(18): 1870\u20132.","DOI":"10.1016\/j.jacc.2022.02.049"},{"issue":"12","key":"1804_CR32","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2020.01.042","volume":"75","author":"G Mendieta","year":"2020","unstructured":"Mendieta G, Ben-Aicha S, Gutierrez M, et al. Intravenous statin administration during myocardial infarction compared with oral post-infarct administration. J Am Coll Cardiol. 2020;75(12):1386\u2013402.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1804_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00380-020-01696-9","volume":"36","author":"T Shimada","year":"2021","unstructured":"Shimada T, Osakada K, Okabe K, et al. Impact of high-dose statin on cardiovascular outcomes in real-world patients with ST-elevation acute myocardial infarction. Heart Vessels. 2021;36(3):297\u2013307.","journal-title":"Heart Vessels"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01804-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01804-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01804-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T02:54:17Z","timestamp":1737082457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01804-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1804"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01804-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4684380\/v1","asserted-by":"object"}]},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}